Revisión De Los Tratamientos Farmacológicos Actuales Y Futuros De La Esteatohepatitis No Alcohólica

Overview

Journal Clin Liver Dis (Hoboken)

Specialty Gastroenterology

Date 2019 May 2

PMID 31041094

Authors

Ahmed Akhter

Abhishek Pulla

Adnan Said

Affiliations

Soon will be listed here.

References

Angulo P . Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346(16):1221-31. DOI: 10.1056/NEJMra011775. View

Harrison S, Torgerson S, Hayashi P, Ward J, Schenker S . Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2003; 98(11):2485-90. DOI: 10.1111/j.1572-0241.2003.08699.x. View

Promrat K, Lutchman G, Uwaifo G, Freedman R, Soza A, Heller T . A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004; 39(1):188-96. DOI: 10.1002/hep.20012. View

McCullough A . The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis. 2004; 8(3):521-33, viii. DOI: 10.1016/j.cld.2004.04.004. View

Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold J . Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005; 293(11):1338-47. DOI: 10.1001/jama.293.11.1338. View

Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N . A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005; 100(5):1082-90. DOI: 10.1111/j.1572-0241.2005.41583.x. View

Sanyal A, Banas C, Sargeant C, Luketic V, Sterling R, Stravitz R . Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006; 43(4):682-9. DOI: 10.1002/hep.21103. View

Machado M, Marques-Vidal P, Cortez-Pinto H . Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006; 45(4):600-6. DOI: 10.1016/j.jhep.2006.06.013. View

Lirussi F, Mastropasqua E, Orando S, Orlando R . Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev. 2007; (1):CD005165. PMC: 8865955. DOI: 10.1002/14651858.CD005165.pub2. View

10.

Lincoff A, Wolski K, Nicholls S, Nissen S . Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007; 298(10):1180-8. DOI: 10.1001/jama.298.10.1180. View

11.

Idilman R, Mizrak D, Corapcioglu D, Bektas M, Doganay B, Sayki M . Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2008; 28(2):200-8. DOI: 10.1111/j.1365-2036.2008.03723.x. View

12.

Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L . Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008; 135(1):100-10. DOI: 10.1053/j.gastro.2008.03.078. View

13.

Aithal G, Thomas J, Kaye P, Lawson A, Ryder S, Spendlove I . Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008; 135(4):1176-84. DOI: 10.1053/j.gastro.2008.06.047. View

14.

Gastaldelli A, Harrison S, Belfort-Aguilar R, Hardies L, Balas B, Schenker S . Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology. 2009; 50(4):1087-93. DOI: 10.1002/hep.23116. View

15.

Juurlink D, Gomes T, Lipscombe L, Austin P, Hux J, Mamdani M . Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ. 2009; 339:b2942. PMC: 2728804. DOI: 10.1136/bmj.b2942. View

16.

Haukeland J, Konopski Z, Eggesbo H, von Volkmann H, Raschpichler G, Bjoro K . Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol. 2009; 44(7):853-60. DOI: 10.1080/00365520902845268. View

17.

Garinis G, Fruci B, Mazza A, De Siena M, Abenavoli S, Gulletta E . Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes (Lond). 2010; 34(8):1255-64. DOI: 10.1038/ijo.2010.40. View

18.

Sanyal A, Chalasani N, Kowdley K, McCullough A, Diehl A, Bass N . Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010; 362(18):1675-85. PMC: 2928471. DOI: 10.1056/NEJMoa0907929. View

19.

Lewis J, Ferrara A, Peng T, Hedderson M, Bilker W, Quesenberry Jr C . Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011; 34(4):916-22. PMC: 3064051. DOI: 10.2337/dc10-1068. View

20.

Lavine J, Schwimmer J, Van Natta M, Molleston J, Murray K, Rosenthal P . Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011; 305(16):1659-68. PMC: 3110082. DOI: 10.1001/jama.2011.520. View